Skip to main content
Premium Trial:

Request an Annual Quote

Hedge Funds, Schmedge Funds, It's A $3 Billion Offer

On the Wall Street Journal health blog, Jacob Goldstein discusses the "battle" for the diagnostic company Ventana -- Roche made a hostile bid for the company earlier this year. Goldstein reports that Roche's CEO, Franz Hume, has been saying that hedge funds have bought out the leading shareholders but that Roche's $3 billion offer will eventually go through.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.